Oxford Biomedica

We’re exhibiting at Cell 2024 next week in London and we’d love to connect! If you’re interested in discussing your viral vector development and manufacturing needs with us, please stop by our booth or reach out to us at partnering@oxb.com to schedule a meeting. Don't miss the opportunity to listen to André Raposo, a Director in our Department of Innovation, present at the conference on 7th November in Track 3 on two key advancements in lentiviral vector production. #BIOEurope #Cell2024 #Conferences #ViralVectors #CDMO #GeneTherapy #Partnering #OXB #Biotech

The tech transfer of our LentiVector™ platform to our Bedford site is a cornerstone of our multi-vector, multi-site model that spans the UK, US and EU. In this video, John Maravich, Site Head of US Operations, delves into the core strategies involved in the tech transfer process, and shares how his team collaborates across our global site network to ensure the highest standards of consistency and quality for our viral vectors. This tech transfer underscores our commitment to be able to offer our clients the flexibility to access all our viral vector CDMO services across our multi-site network. Please email us at partnering@oxb.com if you’d like to learn more. #CDMO #ViralVectors #CellAndGeneTherapy #Innovation #GlobalOperations #OXB #Leadership #Collaboration #TechTransfer 

Meet Stéphanie COLLOUD, Site Head and General Manager of France Operations at OXB! In this video, Stephanie highlights the pivotal role our French sites in Lyon and Strasbourg play in enabling us to support our clients deliver their life-changing therapies to patients. She shares how these locations are driving innovation and collaboration within the global OXB network and the strategic importance of expanding our capabilities into the EU. Watch now to see how our operations in France are ensuring we meet growing client demand for our CDMO services. #CDMO #ViralVectors #CellAndGeneTherapy #Innovation #GlobalOperations #EUExpansion #OXB #Leadership #Collaboration #Innovation #OXB

Meet André Raposo, a Director in our Innovation Department at OXB (UK), as he shares insights into the areas his teams are responsible for at OXB, including their vital role in accelerating analytical development. Through the introduction of automated systems, we have increased the throughput, breadth, and speed of analytical testing, including PCR, cell culture, ELISA, mass spectrometry and RCL testing to ensure the safety of our lentiviral vectors. If you’re curious to learn more about the impact André and his team are making at OXB, you can listen to Andre present at Cell 2024 on 7th November at 15:10 GMT. We hope to see you there! #Innovation #AnalyticalDevelopment #Leadership #Biotech #Teamwork #ClientSuccess #ViralVectors #CellAndGeneTherapy

Our team are at ESGCT this week! If you haven’t visited them yet, they can be found at booth #B36. #ESGCT #Conference #CellAndGeneTherapy #ViralVectors #CDMO

Are you attending ESGCT next week and interested in learning more about our LentiVector and inAAVate platform technologies? Be sure to visit our posters, presented by three of our team members between 22-24 October. Alternatively, stop by booth #B36 to speak to a member of our BD team and learn how we can support your lentiviral vector and AAV programmes. #ESGCT #Conference #CDMO #CellAndGeneTherapy #ViralVectors #AAV #LentiviralVectors #Innovation

The countdown to ESGCT has begun, and we're excited to be heading to Rome next week! If you'll be attending the conference from October 22-25 and would like to meet with us, you can find Sandrine Lopes, Ahmed YAHIA, and Edouard Weill from our BD team at booth #B36. Feel free to stop by our booth or contact them in advance to schedule a meeting. We look forward to connecting with you! #ESGCT #Conference #CDMO #CellAndGeneTherapy #ViralVectors #AAV #LentiviralVectors #Innovation

We recently launched our 4 new company values that guide us in transforming lives through cell and gene therapy. Our new values form the foundation of our OXB DNA, shaping the way we do business, collaborate as a team, and engage with all our stakeholders. Learn more about what each of these new values means to us in the carousel below. 🔹 Responsible 🔹Responsive 🔹 Resilient 🔹 Respect #CDMO #CellAndGeneTherapy #ViralVectors #LentiviralVector #GMP #Manufacturing 

Are you curious to know how we accelerate process development timelines and tackle the complexities of scaling up viral vector production? Listen to our conversation with Dr. Nicholas Clarkson, Head of Process Development at OXB to find out. #CDMO #CellAndGeneTherapy #ViralVectors #AdvancedTherapies #Innovation #ProcessDevelopment

In our latest case study, we are excited to share how we partnered with a client developing a T-cell directed CAR therapy and helped them maximize lentiviral vector (LV) yield using our LentiVector® platform. By employing a custom Design of Experiments approach, we identified optimal process conditions that significantly boosted LV production and performance. We reported an 11-fold increase in LV yield using our U1 snRNA titre enhancing technology, and this project has now advanced to our GMP manufacturing facilities. If you have an LV project you’d like support with, please email partnering@oxb.com to schedule a meeting with us. #CDMO #CellAndGeneTherapy #ViralVectors #LentiviralVector #GMP #Manufacturing